Chickenpox Vaccine Market Scope
Chickenpox is very common across the world for which there is a chickenpox vaccine given as a shot that can protect almost everyone from chickenpox disease as it is caused by the virus called varicella-zoster and is made from the live but weakened or attenuated virus. It has greatly reacted and reduced the number of people from catching chickenpox, two doses of the chickenpox vaccine are about 94% effective. Most of the people who get the shot of vaccines don't get chickenpox and those who do generally get the milder level of the disease. It is widely available in public healthcare clinics, and hospitals, between 70% and 90% of people vaccinated will be completely immune to chickenpox.
Attributes | Details |
---|
Study Period | 2018-2030 |
Base Year | 2023 |
Unit | Value (USD Million) |
Key Companies Profiled | Merck & Co., Inc. (United States), Biken Group (Japan), Green Cross Health Ltd. (New Zealand), GlaxoSmithKline plc. (United Kingdom), Novo (India), Sanofi S.A. (France), Mitsubishi Tanabe Pharma Corporation (Japan) and The Takeda Pharmaceutical Company Limited (Japan) |
CAGR | % |
The companies are exploring the market by adopting mergers & acquisitions, expansions, investments, new product launches, and collaborations as their preferred strategies. The players explore new geographies through expansions and acquisitions to avail a competitive advantage through combined synergies. Research Analyst at AMA estimates that Global Players will contribute to the maximum growth of Global Chickenpox Vaccine market throughout the predicted period.
Merck & Co., Inc. (United States), Biken Group (Japan), Green Cross Health Ltd. (New Zealand), GlaxoSmithKline plc. (United Kingdom), Novo (India), Sanofi S.A. (France), Mitsubishi Tanabe Pharma Corporation (Japan) and The Takeda Pharmaceutical Company Limited (Japan) are some of the key players that are part of study coverage.
About Approach
The research aims to propose a patent-based approach in searching for potential technology partners as a supporting tool for enabling open innovation. The study also proposes a systematic searching process of technology partners as a preliminary step to select the emerging and key players that are involved in implementing market estimations. While patent analysis is employed to overcome the aforementioned data- and process-related limitations, as expenses occurred in that technology allows us to estimate the market size by evolving segments as target market from the total available market.
Segmentation Overview
The study have segmented the market of Global Chickenpox Vaccine market by Type , by Application (Hospitals, Clinics and Laboratories) and Region with country level break-up.
On the basis of geography, the market of Chickenpox Vaccine has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico).
region held largest market share in the year 2023.
Market Leaders and their expansionary development strategies
In July 2022, South Korean biotech company GC LabCell signed a definitive merger agreement with South Korean varicella vaccine biotech company GC Cell Corporation. The transaction brings together two leading South Korean biopharmaceutical companies with complementary portfolios, a strong comprehensive cell therapy R&D pipeline, and state-of-the-art manufacturing capabilities to accelerate growth and accelerate prosperity.
In August 2020, during the pandemic, GSK announced the commencement of a DTC campaign for the Shingrix vaccine aimed toward the older population for varicella-zoster virus inoculation.
"The first chickenpox vaccine was licensed by the Food and Drug Administration in 1995 and is widely available in private doctors' offices and public health clinics. A combination of measles, mumps, rubella, and varicella (MMRV) vaccine was licensed in the United States in 2005 for use among healthy children aged 12 months-12 years. All healthy children 12 months through 12 years of age should have two doses of the chickenpox vaccine, administered at least 3 months apart. Children who have evidence of immunity to varicella do not need the vaccine. People 13 years of age and older who do not have evidence of immunity should get two doses of the vaccine 4 to 8 weeks apart. Chickenpox vaccination is especially important for certain groups of susceptible adults."
Influencing Trend:
Continuous Research and Development in Chickenpox Vaccination
Market Growth Drivers:
Growing Health Awareness Across the World, Need for Preventive Vaccination from Contagious Diseases and Stringent Regulatory Guidelines Regarding Chickenpox
Challenges:
High Cost of Vaccines
Restraints:
Side Effects Like Pain, Swelling, Redness, and Low Fever are Associated with Chickenpox Vaccine
Opportunities:
Awareness about Chickenpox and the Importance of Receiving the Vaccination in Rural regions of the Countries
Key Target Audience
Chickenpox Vaccine Manufacturers, Chickenpox Vaccine International Traders, Chickenpox Vaccine Distributors and Suppliers, Research and Development Institutes, Potential Investors, Industry Associations, Regulatory Bodies, Upstream and Downstream Buyers and Others